Efficacy evaluation of lead compounds in relevant disease animal models is pivotal for the preclinical candidate selection in drug discovery. HD Biosciences has established multiple in vivo animal models to evaluate novel drugs for CNS disorders, cancer, metabolic diseases, inflammation and autoimmune diseases. Each disease model is designed to understand specific aspects of drug property and its mechanism of action. By accessing our comprehensive capability, our customers can advance their drug discovery programs in a time and cost-effective manner. |